AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a from of ovarian cancer.

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo

REUTERS: AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a from of ovarian cancer.

The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or death by 70per cent when compared to placebo.

Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, the companies said.

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Bernard Orr)

Source: Reuters

Bookmark